Management of B-Cell Lymphoma: Where Are We Now and Where Are We Going?

This symposium took place on 15th June 2017, as part of the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland

Chairperson: Gilles Salles1
Speakers: Nathan H. Fowler,2 Umberto Vitolo3

1. Haematology Department, Lyon-Sud University Hospital Complex, Pierre-Bénite, France
2. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3. Department of Oncology and Haematology, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy

Disclosure: Prof Salles reports personal fees for consultancy, participation in symposia, or participation in advisory boards from Amgen, Bristol-Myers Squibb, Celgene, Gilead, Janssen, Kite, Merck, Morphosys, Novartis, Roche, and Servier, and has received a research grant from Roche. Prof Fowler reports grants from Celgene, Roche, and Abbvie, and personal fees from Celgene, Roche, Gilead, and Abbvie. Prof Vitolo reports receiving honoraria for participation in advisory boards for Roche, Janssen, and Celgene, and lecture fees from Roche, Celgene, Janssen, Gilead, and Takeda.
Acknowledgements: Writing assistance was provided by Savroop Bhamra, ApotheCom, London, UK.
Support: The publication of this article was funded by Celgene. The views and opinions expressed are those of the authors and not necessarily those of Celgene.
Citation: EMJ. 2017;2[3]:38-45.

Meeting Summary

The main objectives of the symposium were to explore the current developments in the diagnosis and treatment of non-Hodgkin lymphoma (NHL). An overview of the hurdles and unmet needs in the management of indolent NHL were discussed, followed by the current and future perspectives for the treatment of indolent NHL. The topic of frontline treatment outcomes in diffuse large B-cell lymphoma (DLBCL), the most common type of high-grade NHL, was also explored with an emphasis on how outcomes could be improved.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 207KB)

Comments are closed.